{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:46Z","timestamp":1791262366717,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the frequency of clinically relevant interactions between TKIs and PPIs in clinical practice and the duration of concomitant prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was performed using the IADB.nl prescription database. Clinically relevant drug\u2013drug interactions between TKIs and PPIs were assessed using four drug compendia (i.e., KNMP Kennisbank, Health Base, Lexidrug and Merative Micromedex). Patients who were prescribed a TKI and PPI with a clinically relevant DDI concomitantly, between 1 January 2013 and 31 December 2024, were included. Concomitant prescription was defined as \u2265\u20097\u2009days of simultaneous prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In total, 60 TKIs were registered in the Netherlands; 19 TKIs had clinically relevant interactions reported by at least one compendium. Overall, 393 of 1759 (22.3%) TKI users had a clinically relevant interaction. The median duration of concomitant prescription was 43\u2009days (IQR = 81), with 91.1% of episodes lasting at least 30\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PPIs and TKIs are frequently prescribed concomitantly in clinical practice. Prescribers should be more cautious when co\u2010prescribing PPIs with TKIs and adapt the dosing regimens when appropriate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcpt.70317","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:19:02Z","timestamp":1791260342000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Frequency of Clinically Relevant Drug\u2013Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real\u2010World Data"],"prefix":"10.1111","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9293-9441","authenticated-orcid":false,"given":"Grietje","family":"van Elp","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Deventer Hospital  Deventer the Netherlands"},{"name":"Unit of PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2561-4059","authenticated-orcid":false,"given":"Maikel","family":"Borg","sequence":"additional","affiliation":[{"name":"Unit of PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-7564","authenticated-orcid":false,"given":"Jens H. J.","family":"Bos","sequence":"additional","affiliation":[{"name":"Unit of PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C. M.","family":"Schuiling\u2010Veninga","sequence":"additional","affiliation":[{"name":"Unit of PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-2004","authenticated-orcid":false,"given":"Katja","family":"Taxis","sequence":"additional","affiliation":[{"name":"Unit of PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-9578","authenticated-orcid":false,"given":"Frank G. A.","family":"Jansman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Deventer Hospital  Deventer the Netherlands"},{"name":"Unit of PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Tyrosine Kinase Inhibitors","author":"Thomson R. J.","year":"2023"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.12.1494"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400403s"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572\u20100241.2007.01106.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39406.449456.BE"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102036.2012.05014.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102036.1997.00182.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010016\u20100503\u20103"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102794"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001356"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31917"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.526"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.05.019"},{"key":"e_1_2_8_15_1","unstructured":"IADB.nl \u201cDrug Use Research \u201d (2026). assessed 16\u201001\u20102026 https:\/\/iadb.nl\/."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.13.20"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70159"},{"key":"e_1_2_8_18_1","unstructured":"Kennisbank \u201cTKI's + Secretieremmers (822\u20131) \u201d accessed 16\u201001\u20102026 http:\/\/kennisbank.knmp.nl\/article\/medisch_farmaceutische_beslisregels\/protocol\/822\u20101.html."},{"key":"e_1_2_8_19_1","unstructured":"Commentaren medicatiebewaking. accessed 16\u201001\u20102026 https:\/\/www.commentarenmedicatiebewaking.nl\/."},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","unstructured":"UpToDate \u201cDrug Interactions \u201d accessed 17\u201001\u20102026 https:\/\/www.uptodate.com\/drug\u2010interactions.","DOI":"10.1097\/01.EEM.0000000000000226"},{"key":"e_1_2_8_21_1","unstructured":"Micromedex \u201cDrug Interaction Databse \u201d accessed 16\u201001\u20102026 https:\/\/www.micromedexsolutions.com\/home\/dispatch."},{"key":"e_1_2_8_22_1","unstructured":"College ter Beoordeling van Geneesmiddelen \u201cGeneesmiddeleninformatiebank \u201d (2015). accessed 16\u201001\u20102026 https:\/\/www.geneesmiddeleninformatiebank.nl."},{"key":"e_1_2_8_23_1","unstructured":"Norwegian Institute of Public Health \u201cATC\/DDD index \u2010 Updates Included in the ATC\/DDD Index \u201d (2026). accessed 16\u201001\u20102026 https:\/\/atcddd.fhi.no\/atc_ddd_index\/updates_included_in_the_atc_ddd_index\/."},{"key":"e_1_2_8_24_1","unstructured":"European Medicines Agency (EMA) \u201cMedicines \u201d (2023) https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"e_1_2_8_25_1","unstructured":"European Medicines Agency \u201cCalquence (Acalabrutinib): Summary of Product Characteristics \u201d (2025) https:\/\/www.ema.europa.eu."},{"key":"e_1_2_8_26_1","unstructured":"European Medicines Agency \u201cTafinlar (Dabrafenib): Summary of Product Characteristics \u201d (2026) https:\/\/www.ema.europa.eu."},{"key":"e_1_2_8_27_1","unstructured":"European Medicines Agency \u201cTasigna (Nilotinib): Summary of Product Characteristics \u201d (2025) https:\/\/www.ema.europa.eu."},{"key":"e_1_2_8_28_1","unstructured":"European Medicines Agency \u201cRetsevmo (Selpercatinib): Summary of Product Characteristics \u201d (2026) https:\/\/www.ema.europa.eu."},{"key":"e_1_2_8_29_1","unstructured":"European Medicines Agency \u201cNexavar (Sorafenib): Summary of Product Characteristics \u201d (2025) https:\/\/www.ema.europa.eu."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000212"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2006.02809.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.2196\/11182"},{"key":"e_1_2_8_33_1","unstructured":"European Medicines Agency \u201cVotrient (Pazopanib): Summary of Product Characteristics \u201d (2025) https:\/\/www.ema.europa.eu."},{"key":"e_1_2_8_34_1","unstructured":"Zorginstituut Nederland \u201cInfographic \u2010 What Is the Lock Procedure for Expensive Medicinal Products? \u201d (2026). Accessed 20\u201008\u20102026 https:\/\/english.zorginstituutnederland.nl\/about\u2010us\/working\u2010methods\u2010and\u2010procedures\/lock\u2010procedure\u2010for\u2010expensive\u2010medicinal\u2010products\/infographic\u2010\u2010\u2010what\u2010is\u2010the\u2010lock\u2010procedure\u2010for\u2010expensive\u2010medicinal\u2010products."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/23333928241241220"},{"key":"e_1_2_8_36_1","unstructured":"Stichting Farmaceutische Kengetallen (SFK) \u201cMeer maagmiddelen voor minder \u201d Den Haag: SFK; (2009). accessed 17\u201009\u20102026 https:\/\/www.sfk.nl\/publicatie\/2009\/pw\u2010artikel\/meer\u2010maagmiddelen\u2010voor\u2010minder."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13843"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010020\u201003014\u20108"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00967"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14372"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5362"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.70317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:19:07Z","timestamp":1791260347000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.70317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/bcpt.70317"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.70317","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"2026-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70317"}}